An update on the use of transmucosal fentanyl in patients suffering from cancer-related pain (long version)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Aronoff GM, Brennan MJ, Pritchard DD, Ginsberg B (2005) Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. Pain Medicine 6:305–314
Blick SK, Wagstaff AJ (2006) Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. Drugs 66:2387–2393
Darwish M, Kirby M, Jiang JG, et al (2008) Bioequivalence following buccal and sublingual placement of fentanyl buccal tablet 400 μg in healthy subjects. Clin Drug Invest 28:1–7
Darwish M, Kirby M, Robertson P, et al (2006) Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet 45:843–850
Darwish M, Kirby M, Robertson P, et al (2007) Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis. A pilot study. Clin Drug Invest 27:605–611
Kaasa S, Moksnes K, Nolte T, et al. (2010) Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain. J Opioid Manage 6:17–26
Lee M, Kern SE, Kisicki JC, Egan TD (2003) A pharmacokinetic study to compare two simultaneous 400 μg doses with a single 800 μg dose of oral transmucosal fentanyl citrate. J Pain Symptom Manage 26:743–747
Lennernäs B, Hedner T, Holmberg M, et al (2004) Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 59:249–253